Abiogen Pharma: an active role in the respiratory area since the beginning
Since the beginning, Abiogen Pharma has operated in the Respiratory Area in close collaboration with general practitioners and various healthcare professionals including nose and throat specialists, lung specialists, and pediatricians, offering solutions for the management of respiratory infections.
Respiratory infections, both acute and chronic, are extremely common in both adults and children. These infections can be acquired in the community or hospitals.
Non-immunosuppressed and immunosuppressed patients can develop these health problems, although the prevalence is higher in the latter group. The pathogen can be viral, bacterial, fungal, or parasitic. In recent years, the role of respiratory viruses has become increasingly dominant.
Respiratory infections are particularly challenging among the elderly due to their frailty and the chronic conditions associated with this age group. Additionally, older individuals have a greater susceptibility to infections and show increased mortality and morbidity as the immune system’s ability to fight infections decreases with age.
Upper respiratory tract infections
Upper respiratory tract infections are localized in the upper respiratory tract, which includes: mouth, nose, throat, larynx (voice box), and trachea. They may include any of the following conditions:
- Rhinopharyngitis (common cold)
Although upper respiratory tract infections can occur at any time, they are more common in the fall and winter months, from September to March, as these are the school months when children and adolescents spend a lot of time in groups and indoors.
Lower respiratory tract infections
Lower respiratory tract infections include acute bronchitis, influenza, community-acquired pneumonia, acute exacerbation of COPD, and acute exacerbation of bronchiectasis.
They are one of the leading causes of death worldwide and often affect the most vulnerable: children, elderly and frail people.
Healthcare professionals caring for patients with lower respiratory tract infections must address various challenges, including a growing number of immunosuppressed patients.